Takeda M, Shimokawa M, Nakamura A, Nosaki K, et al. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M- Clin Lung Cancer 2021;22:376-380.
PMID: 33612406